/PRNewswire/ Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021..
E-Mail
An experimental treatment can essentially reverse type 1 diabetes in certain types of laboratory mice, according to a series of studies led by University of Utah Health scientists. An injection of the therapeutic agent converts cells that normally control glucose production into ones that generate insulin.
The researchers say giving the animals a single dose of a human antibody that suppress the actions of glucagon, a hormone involved in glucose regulation, sparked a remarkable transformation in the pancreas, leading to a nearly 7-fold increase in insulin cell mass and the suppression of diabetic symptoms. These animals go from requiring insulin injections to never requiring a diabetes treatment again. They maintain normal blood glucose long after we stop the treatment, says William L. Holland, Ph.D., the study s corresponding author and a U of U Health assistant professor of Nutrition and Integrative Physiology. What this implies for millions of people who have type
Editas Medicine
James Mullen takes over as CEO from Feb. 15.
Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief
Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from
Feb 9, 2021 8:11am
Eli Lilly tapped a new CFO after finding its former top finance exec engaged in consensual though inappropriate personal communications with employees.
After Eli Lilly heard allegations of an inappropriate relationship between its chief financial officer, Josh Smiley, and an employee, the drugmaker hired an external firm to investigate. Now, Smiley is not only out of the job, but also forfeiting $24 million in cash and equity awards.
Smiley, who s served as CFO since the start of 2018, is leaving the company, Lilly said Tuesday. Anat Ashkenazi, previously senior vice president, controller and chief financial officer of Lilly Research Laboratories, will take the post.